Ginkgo Bioworks builds biological components as a platform — programming microorganisms to produce medicines, foods, fragrances, and materials. Their Foundry has become the AWS of synthetic biology, enabling companies to outsource cell programming. Ginkgo went public via SPAC in 2021 at a $15B valuation, though shares declined significantly afterward.
IPO details
IPO date
Fri Sep 17
IPO price
—
First-day close
—
IPO valuation
$645M
Market-data summary
Current price
—
Market cap
—
Day range
—
52-week range
—
Data last checked Wed Sep 23. Optional market data is not yet available where shown as —.